Literature DB >> 25994220

Novel evidence for an oncogenic role of microRNA-21 in colitis-associated colorectal cancer.

Chenzhang Shi1, Yongzhi Yang1, Yang Xia2, Yoshinaga Okugawa3, Jun Yang2, Yong Liang2, Hongqi Chen2, Peng Zhang1, Feng Wang1, Huazhong Han2, Wen Wu1, Renyuan Gao1, Christoph Gasche4, Huanlong Qin1, Yanlei Ma1, Ajay Goel3.   

Abstract

OBJECTIVE: miR-21 was found to be overexpressed in the colon tissues and serum of patients with UC and colorectal cancer (CRC); however, the exact roles of miR-21 in colitis-associated CRC remain unclear. The aim of our study was to investigate the biological mechanisms of miR-21 in colitis-associated colon cancer (CAC).
DESIGN: miR-21 expression was examined in the tumours of 62 patients with CRC from China and 37 colitis-associated neoplastic tissues from Japan and Austria. The biological functions of miR-21 were studied using a series of in vitro, in vivo and clinical approaches.
RESULTS: miR-21 levels were markedly upregulated in the tumours of 62 patients with CRC, 22 patients with CAC, and in a mouse model of CAC. Following azoxymethane and dextran sulfate sodium intervention, miR-21-knockout mice showed reduced expression of proinflammatory and procarcinogenic cytokines (interleukin (IL) 6, IL-23, IL-17A and IL-21) and a decrease in the size and number of tumours compared with the control mouse group. The absence of miR-21 resulted in the reduced expression of Ki67 and the attenuated proliferation of tumour cells with a simultaneous increase in E-cadherin and decrease in β-catenin and SOX9 in the tumours of CAC mice. Furthermore, the absence of miR-21 increased the expression of its target gene PDCD4 and subsequently modulated nuclear factor (NF)-κB activation. Meanwhile, miR-21 loss reduced STAT3 and Bcl-2 activation, causing an increase in the apoptosis of tumour cells in CAC mice.
CONCLUSIONS: These observations provide novel evidence for miR-21 blockade to be a key strategy in reducing CAC. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Keywords:  CANCER; COLORECTAL CANCER

Mesh:

Substances:

Year:  2015        PMID: 25994220     DOI: 10.1136/gutjnl-2014-308455

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  67 in total

1.  MicroRNAs as potential liquid biopsy biomarkers in colorectal cancer: A systematic review.

Authors:  Yuji Toiyama; Yoshinaga Okugawa; James Fleshman; C Richard Boland; Ajay Goel
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2018-05-29       Impact factor: 10.680

2.  TGR5 Protects Against Colitis in Mice, but Vertical Sleeve Gastrectomy Increases Colitis Severity.

Authors:  Darline Garibay; Karolina E Zaborska; Michael Shanahan; Qiaonan Zheng; Katie M Kelly; David C Montrose; Andrew J Dannenberg; Andrew D Miller; Praveen Sethupathy; Bethany P Cummings
Journal:  Obes Surg       Date:  2019-05       Impact factor: 4.129

3.  FOXM1 and FOXQ1 Are Promising Prognostic Biomarkers and Novel Targets of Tumor-Suppressive miR-342 in Human Colorectal Cancer.

Authors:  Wenhao Weng; Yoshinaga Okugawa; Shusuke Toden; Yuji Toiyama; Masato Kusunoki; Ajay Goel
Journal:  Clin Cancer Res       Date:  2016-05-09       Impact factor: 12.531

4.  MicroRNA MIR21 (miR-21) and PTGS2 Expression in Colorectal Cancer and Patient Survival.

Authors:  Kosuke Mima; Reiko Nishihara; Juhong Yang; Ruoxu Dou; Yohei Masugi; Yan Shi; Annacarolina da Silva; Yin Cao; Mingyang Song; Jonathan Nowak; Mancang Gu; Wanwan Li; Teppei Morikawa; Xuehong Zhang; Kana Wu; Hideo Baba; Edward L Giovannucci; Jeffrey A Meyerhardt; Andrew T Chan; Charles S Fuchs; Zhi Rong Qian; Shuji Ogino
Journal:  Clin Cancer Res       Date:  2016-03-08       Impact factor: 12.531

5.  Propofol inhibits growth and invasion of pancreatic cancer cells through regulation of the miR-21/Slug signaling pathway.

Authors:  Zimin Liu; Jian Zhang; Guangchen Hong; Jinping Quan; Lin Zhang; Meiqin Yu
Journal:  Am J Transl Res       Date:  2016-10-15       Impact factor: 4.060

6.  Fusobacterium nucleatum Increases Proliferation of Colorectal Cancer Cells and Tumor Development in Mice by Activating Toll-Like Receptor 4 Signaling to Nuclear Factor-κB, and Up-regulating Expression of MicroRNA-21.

Authors:  Yongzhi Yang; Wenhao Weng; Junjie Peng; Leiming Hong; Lei Yang; Yuji Toiyama; Renyuan Gao; Minfeng Liu; Mingming Yin; Cheng Pan; Hao Li; Bomin Guo; Qingchao Zhu; Qing Wei; Mary-Pat Moyer; Ping Wang; Sanjun Cai; Ajay Goel; Huanlong Qin; Yanlei Ma
Journal:  Gastroenterology       Date:  2016-11-19       Impact factor: 22.682

Review 7.  The Role of Non-Coding RNAs and Isothiocyanates in Cancer.

Authors:  Samantha L Martin; Kendra J Royston; Trygve O Tollefsbol
Journal:  Mol Nutr Food Res       Date:  2018-05-28       Impact factor: 5.914

8.  Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial.

Authors:  Keisuke Kosumi; Tsuyoshi Hamada; Sui Zhang; Li Liu; Annacarolina da Silva; Hideo Koh; Tyler S Twombly; Kosuke Mima; Teppei Morikawa; Mingyang Song; Jonathan A Nowak; Reiko Nishihara; Leonard B Saltz; Donna Niedzwiecki; Fang-Shu Ou; Tyler Zemla; Robert J Mayer; Hideo Baba; Kimmie Ng; Marios Giannakis; Xuehong Zhang; Kana Wu; Edward L Giovannucci; Andrew T Chan; Charles S Fuchs; Jeffrey A Meyerhardt; Shuji Ogino
Journal:  Eur J Cancer       Date:  2019-03-01       Impact factor: 9.162

Review 9.  MicroRNAs: Novel immunotherapeutic targets in colorectal carcinoma.

Authors:  Xiang Li; Jing Nie; Qian Mei; Wei-Dong Han
Journal:  World J Gastroenterol       Date:  2016-06-21       Impact factor: 5.742

Review 10.  Colorectal Cancer and Dysplasia in Inflammatory Bowel Disease: A Review of Disease Epidemiology, Pathophysiology, and Management.

Authors:  Parambir S Dulai; William J Sandborn; Samir Gupta
Journal:  Cancer Prev Res (Phila)       Date:  2016-09-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.